GlassScriptPhysician profile
Hazel-Ann M David
NPI 1356332340
$5,226.08
in general payments reported to CMS, 2019-2025
28 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $297 · 2021: $97.33 · 2022: $533 · 2023: $899 · 2024: $1,418 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.60 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,707.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $853.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $500.15 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.23 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $276.13 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $174.74 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $156.77 | 2022-2025 | Veozah |
| Amgen INC. | $156.13 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $130.80 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Eisai INC. | $122.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $103.05 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $101.15 | 2022-2024 | |
| Amarin Pharma, INC. | $93.44 | 2019-2022 | |
| Abbvie INC. | $66.20 | 2021-2025 | Ubrelvy |
| Allergan, INC. | $42.84 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.22 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $32.62 | 2019 | |
| Inspire Medical Systems, INC. | $31.98 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $29.29 | 2019 | |
| Gilead Sciences, INC. | $23.79 | 2025 | |
| Dynavax Technologies Corporation | $23.43 | 2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $20.73 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $19.88 | 2023 | |
| Biogen, INC. | $18.67 | 2024 | Leqembi |
| Novartis Pharmaceuticals Corporation | $17.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.48 | 2024 | Livalo |
| Boston Scientific Corporation | $14.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel-Ann David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.